Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.
Fernández Ó, Sörensen PS, Comi G, Vermersch P, Hartung HP, Leocani L, Berger T, Van Wijmeersch B, Oreja-Guevara C. Fernández Ó, et al. Among authors: van wijmeersch b. Front Immunol. 2024 Apr 5;15:1379538. doi: 10.3389/fimmu.2024.1379538. eCollection 2024. Front Immunol. 2024. PMID: 38646534 Free PMC article. Review.
Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect.
Sprangers B, Van Wijmeersch B, Luyckx A, Sagaert X, De Somer L, Rutgeerts O, Lenaerts C, Landuyt W, Boeckx N, Dubois B, De Wolf-Peeters C, Waer M, Billiau AD. Sprangers B, et al. Among authors: van wijmeersch b. Leukemia. 2009 Feb;23(2):340-9. doi: 10.1038/leu.2008.298. Epub 2008 Nov 6. Leukemia. 2009. PMID: 18987665
Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression.
Peeters LM, Vanheusden M, Somers V, Van Wijmeersch B, Stinissen P, Broux B, Hellings N. Peeters LM, et al. Among authors: van wijmeersch b. Front Immunol. 2017 Sep 20;8:1160. doi: 10.3389/fimmu.2017.01160. eCollection 2017. Front Immunol. 2017. PMID: 28979263 Free PMC article.
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Wiendl H, Carraro M, Comi G, Izquierdo G, Kim HJ, Sharrack B, Tornatore C, Daizadeh N, Chung L, Jacobs AK, Hogan RJ, Wychowski LV, Van Wijmeersch B; CARE-MS I, CARE-MS II, and CAMMS03409 Investigators. Wiendl H, et al. Among authors: van wijmeersch b. Neurol Neuroimmunol Neuroinflamm. 2019 Oct 29;7(1):e635. doi: 10.1212/NXI.0000000000000635. Print 2020 Jan. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31662412 Free PMC article. Clinical Trial.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P. Van Wijmeersch B, et al. Mult Scler. 2020 Nov;26(13):1719-1728. doi: 10.1177/1352458519881759. Epub 2019 Nov 1. Mult Scler. 2020. PMID: 31675266 Free PMC article.
103 results